Welcome to Paid Research Studies




  • Condition:   Oculocutaneous Albinism
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting

  • Condition:   Hermansky-Pudlak Syndrome (HPS)
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting

  • Condition:   Chediak Higashi Syndrome
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting

  • Condition:   Hermansky Pudlak Syndrome
    Interventions:   Other: Pulmonary function test;   Other: Chest CT;   Other: Sample collection
    Sponsors:   Vanderbilt University;   University of South Florida;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Pulmonary Fibrosis;   Healthy Volunteers;   Hermansky-Pudlak Syndrome (HPS)
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting

  • Conditions:   SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
    Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Immune Deficiency Disorders;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorders;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
    Intervention:   Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
    Sponsor:   Washington University School of Medicine
    Recruiting